Combination immunotherapy and tyrosine kinase inhibitors with immunotherapy in patients with metastatic renal cell carcinoma

04/2020

MUDr. Alexandr Poprach, Ph.D.; MUDr. Radek Lakomý, Ph.D.

Klinika komplexní onkologické péče, LF MU a Masarykův onkologický ústav, Brno

SUMMARY

The treatment of patients with mRCC is still palliative, but recently we have the results of several studies combining modern therapy, where we have seen a significant increase in time to disease progression and overall survival compared to tyrosine kinase inhibitors (TKI), as well as the numbers of overall treatment responses. We must not forget that if there is a therapeutic response to immunotherapy, it is often long-term again compared to TKI, which is particularly underlined for complete remissions. In this review below we will present the current results of three studies combining advanced immunotherapy with TKI or a combination of anti-programmed cell death protein 1 (anti-PD-1) antibody with anti-cytotoxic T-lymphocyte associated antigen 4 (anti-CTLA-4) antibody.

Key words

ipilimumab, nivolumab, avelumab, pembrolizumab, axitinib, overall survival, duration of response